FDMT - 4D Molecular Therapeutics • Financials

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	21	-107	-	L	L	308	L	-288	-	-95	-3	157	-98	0	0	-	-
12/2024	0	-181	-	L	L	511	L	-425	-	-161	-4	337	-164	0	0	-	-
12/2025	85	-152	-	L	L	506	L	-403	-	-131	-1	113	-132	0	0	-	-

To see all financials—including updated, you must be Premium.